By Kimberly Chin


AbbVie Inc. received U.S. Food and Drug Administration approval for its treatment of acute bacterial skin and skin structure infections in children and infants, the company said Friday.

The Dalvance drug is administered intravenously in a single dose. In clinical trials, the treatment was found to reduce lesion size and didn't require rescue antibacterial therapy for children 3 months and older, the company said. The treatment's safety findings in pediatric patients were also similar to those seen in adults, it said.

Such skin infections are caused by Gram-positive pathogens, such as Staphylococcus aureus and Streptococcus pyogenes, and they can be serious and life-threatening, AbbVie said.

AbbVie's shares inched up nearly 1% on Friday to around $118. Its stock has gained 21% in the past 12 months.


Write to Kimberly Chin at


(END) Dow Jones Newswires

July 23, 2021 13:18 ET (17:18 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more AbbVie Charts.
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more AbbVie Charts.